VBL Therapeutics Announces First Quarter 2017 Financial Results
May 15, 2017 07:15 ET | VBL Therapeutics
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting
May 11, 2017 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced new preclinical data indicating that treatment with ofranergene obadenovec (VB-111) augments the...
VBL Therapeutics to Report First Quarter 2017 Results on May 15
May 03, 2017 08:00 ET | VBL Therapeutics
TEL AVIV, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences
April 25, 2017 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that new data on VB-111 will be presented at the upcoming American Society of Clinical Oncology (ASCO)...
VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
April 20, 2017 16:01 ET | VBL Therapeutics
TEL AVIV, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the Independent Data Safety Monitoring Committee (DSMC) met to conduct its second safety...
VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
April 04, 2017 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, April 04, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study,...
VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH
April 03, 2017 07:00 ET | VBL Therapeutics
Phase 2 Study of VB-201 Shows Reduction in Liver Enzymes Data Presented Today at H.C. Wainwright Annual NASH Investor Conference TEL AVIV, Israel, April 03, 2017 (GLOBE NEWSWIRE) -- VBL...
VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference
March 28, 2017 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, March 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results
March 27, 2017 07:30 ET | VBL Therapeutics
Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018Phase 3 Study of VB-111 in Ovarian Cancer Currently Expected to Begin Enrollment in the...
VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology
March 23, 2017 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) announced today that it will be hosting a Key Opinion Leader breakfast on new targets and immunotherapeutic...